PD Dr. Fabian Müller

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology Professur für CAR-T-Zell-Therapie

CD19-targeted CAR T cells in refractory antisynthetase syndrome (2023) Müller F, Böltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, et al. Journal article Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. (2023) Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al. Journal article, Erratum Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL (2023) Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, Iraola-Truchuelo J, et al. Journal article CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial (2023) Mackensen A, Haanen JB, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, et al. Journal article Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. (2023) Bergmann C, Müller F, Distler J, Györfi AH, Völkl S, Aigner M, Kretschmann S, et al. Journal article, Letter CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany (2022) Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Buecklein VL, Bonig H, et al. Conference contribution Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy (2022) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Kremer A, Tenbusch M, et al. Conference contribution CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022) Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al. Conference contribution Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1a-Mediated Apoptosis Following Unfolded Protein Response (2022) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Conference contribution Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity (2022) Pelzl R, Kübel S, Klein P, Gsottberger F, Wendland K, Petkovic S, Brueckl V, et al. Conference contribution